News for Exelixis, Inc. (EXEL)

U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 100 points on Tuesday. Shares of Whirlpool Corporation WHR fell sharply in ...

Exelixis, Inc. (NASDAQ:EXEL) Q2 2025 Earnings Conference Call July 28, 2025 5:00 PM ETCompany Participantsl - Corporate ParticipantAmy C.

U.S. stock markets opened the week with a continuation of their recent upward trend on Monday, July 28, 2025, largely driven by easing trade tensions and

The U.S. stock market experienced a mixed trading session on Monday, July 28, 2025, as investors digested fresh trade developments and braced for a packed

The S&P 500 Index ($SPX ) (SPY ) today is up +0.08%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.02%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.34%. September E-mini S&P futures (ESU25 ) are up +0.04%, and September E-mini Nasdaq futures...

The U.S. stock market is poised for a dynamic start to the week on Monday, July 28, 2025, with premarket trading indicating a positive sentiment driven by a

September S&P 500 E-Mini futures (ESU25) are up +0.28%, and September Nasdaq 100 E-Mini futures (NQU25) are up +0.46% this morning, pointing to a higher open on Wall Street after U.S. President Donald Trump reached a trade deal with the European Union.

Exelixis (EXEL) Q2 earnings report is set for July 28th. Get insights on EPS, revenue trends, revisions, and past performance.

Summary Exelixis Inc (EXEL) announced that its partner Ipsen has received approval from the European Commission for CABOMETYX® (cabozantinib) to treat adult pa

[url="]Exelixis, Inc.[/url] (Nasdaq: EXEL) today announced that its partner Ipsen received approval from the European Commission (EC) for CABOMETYX® (cabozant

Exelixis (EXEL) secures European Commission approval for Cabometyx in collaboration with Ipsen. Analysts target an average price of $45.95, suggesting a

Exelixis, Inc. (NASDAQ:EXEL) is one of the 13 Best Low Risk High Growth Stocks to Buy. The company advances its studies following a significant rise in price targets from analysts. Based in California, Exelixis, Inc. (NASDAQ:EXEL) is a biotechnology company focused on discovering, developing, and commercializing oncology medicines. It is known for its work in […]

Get a deeper insight into the potential performance of Exelixis (EXEL) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.

Morgan Stanley analyst Jefferson Harralson has raised the price target for Exelixis (EXEL) from $47.00 to $48.00, representing a 2.13% increase. The adjustment

Morgan Stanley's analyst, Sean Laaman, has increased the price target for Exelixis (EXEL) from $47 to $48 while maintaining an Overweight rating on the stock. T

Exelixis' most important product should continue driving strong financial results through the end of the decade. A decade ago, shares of Exelixis (NASDAQ: EXEL), a biotech company specializing in oncology, were trading for under $10 per share. In other words, Exelixis has crushed the market since 2015.

Yet another biopharma name has been run through a familiar trading cycle that often ends on a bullish note.

Exelixis (EXEL) has received a fresh update from Truist Securities, as analyst Asthika Goonewardene recently adjusted the stock's price target. The firm has rai

Barclays has adjusted its price target for Exelixis (EXEL), increasing it from $29 to $40, while maintaining an Equal Weight rating on the stock. This revision